Fiona Lawrence
General Counsel at ARECOR THERAPEUTICS PLC
Net worth: 123 061 $ as of 2024-04-29
Profile
Fiona Jane Lawrence is currently the VP-Clinical Development & Regulatory Affairs at Arecor Therapeutics Plc.
Previously, she worked as the Director-Research & Clinical Development at Duchenne UK, Senior Manager-Clinical Research at Prosensa Therapeutics BV, Commercial Trials Manager at Cambridge University Hospitals NHS Foundation Trust, and Senior Manager-Clinical Research at BioMarin Nederland BV.
Ms. Lawrence has an undergraduate degree from the University of Bath and a graduate degree from the University of Surrey.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARECOR THERAPEUTICS PLC
0.24% | 2022-11-15 | 72,000 ( 0.24% ) | 123 061 $ | 2024-04-29 |
Fiona Lawrence active positions
| Companies | Position | Start |
|---|---|---|
| ARECOR THERAPEUTICS PLC | General Counsel | - |
Former positions of Fiona Lawrence
| Companies | Position | End |
|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Corporate Officer/Principal | - |
| BioMarin Nederland BV | Corporate Officer/Principal | - |
| Prosensa Therapeutics BV | Corporate Officer/Principal | - |
Duchenne UK
 Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Chief Tech/Sci/R&D Officer | - |
Training of Fiona Lawrence
| University of Bath | Undergraduate Degree |
| University of Surrey | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARECOR THERAPEUTICS PLC | Health Technology |
| Private companies | 4 |
|---|---|
| Prosensa Therapeutics BV | Health Technology |
| BioMarin Nederland BV | |
Duchenne UK
Duchenne UK Investment Trusts/Mutual FundsMiscellaneous Duchenne UK is a UK-based charity that focuses on finding effective treatments for Duchenne muscular dystrophy (DMD), a progressive condition that weakens all the muscles in the body and is diagnosed in childhood. Additionally, Duchenne connects and supports families affected by DMD. The charity funds research that aims to provide treatments for those affected by DMD and removes roadblocks that prevent patients from accessing the treatments they need. The British company was founded in 2012 by Nick Crossley, Emily Crossley, and Alex Johnson, and Emily Crossley and Alex Johnson have been the CEOs since 2012. | Miscellaneous |
| Cambridge University Hospitals NHS Foundation Trust | Health Services |
- Stock Market
- Insiders
- Fiona Lawrence